russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2017-6-164-166russjcardiol-2474Research ArticleКЛИНИКА И ФАРМАКОТЕРАПИЯGUIDELINES FOR THE PRACTITIONERК ВОПРОСУ О БЕЗОПАСНОСТИ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ ПРЯМОГО ДЕЙСТВИЯ В ПОВСЕДНЕВНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕCONCERNING THE SAFETY OF THE DIRECT ORAL ANTICOAGULANTS IN ROUTINE CAREРезолюцияСовета ЭкспертовExpertBoard Resolution20172107201706164166Copyright © Резолюция С.Э., 20172017Резолюция С.Э.Expert B.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/2474
.
.
ReferencesRawlins M. Therapeutic Evidence and Decision-making; Hodder Arnold; London, 2011; 230 p.Rawlins M. Therapeutic Evidence and Decision-making; Hodder Arnold; London, 2011; 230 p.Garrison L, Neumann L, Erickson P, et al. Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report. Value in Health 2007; 10 (5): 326-35.Garrison L, Neumann L, Erickson P, et al. Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report. Value in Health 2007; 10 (5): 326-35.Berger M, Mamdani M, Atkins D, et al. Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report–Part I. Value in Health 2009; 12(8): 1044-52.Berger M, Mamdani M, Atkins D, et al. Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report–Part I. Value in Health 2009; 12(8): 1044-52.Hannan E. Randomized Clinical Trials and Observational Studies. Guidelines for Assessing Respective Strengths and Limitations. J Am Coll Cardiol Intv 2008; 1: 211-7.Hannan E. Randomized Clinical Trials and Observational Studies. Guidelines for Assessing Respective Strengths and Limitations. J Am Coll Cardiol Intv 2008; 1: 211-7.Connolly SJ, Ezekowitz M, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139-51.Connolly SJ, Ezekowitz M, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139-51.Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.Granger CB, Alexander JH, McMurray JW, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365: 981-92.Granger CB, Alexander JH, McMurray JW, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365: 981-92.Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation Circulation 2015; 131: 157-64.Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation Circulation 2015; 131: 157-64.Gorst-Rasmussen A, Lip GYH, Larsen TB. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf 2016; 25(11): 1236-44.Gorst-Rasmussen A, Lip GYH, Larsen TB. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf 2016; 25(11): 1236-44.Graham DJ, Reichman ME, Wernecke M. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med. 2016; 176(11): 1662-71.Graham DJ, Reichman ME, Wernecke M. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med. 2016; 176(11): 1662-71.Hernandez I, Zhang Y. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. Am J Cardiovasc Drugs 2017; 17: 37-47.Hernandez I, Zhang Y. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. Am J Cardiovasc Drugs 2017; 17: 37-47.
The authors declare that there are no conflicts of interest present.